Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions

Effective treatment of advanced/metastatic bone and soft tissue sarcomas still represents an unmet medical need. Recent advances in targeted therapies have highlighted the potential of cyclin-dependent kinases (CDK) inhibitors in several cancer types, including sarcomas. CDKs are master regulators o...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2023-01, Vol.13, p.1095219-1095219
Main Authors: Merlini, Alessandra, Pavese, Valeria, Manessi, Giulia, Rabino, Martina, Tolomeo, Francesco, Aliberti, Sandra, D'Ambrosio, Lorenzo, Grignani, Giovanni
Format: Article
Language:English
Subjects:
cdk inhibitors
cell cycle
cyclin dependent kinases (CDK)
Oncology
sarcoma
target therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Effective treatment of advanced/metastatic bone and soft tissue sarcomas still represents an unmet medical need. Recent advances in targeted therapies have highlighted the potential of cyclin-dependent kinases (CDK) inhibitors in several cancer types, including sarcomas. CDKs are master regulators of the cell cycle; their dysregulation is listed among the "hallmarks of cancer" and sarcomas are no exception to the rule. In this review, we report both the molecular basis, and the potential therapeutic implications for the use of CDK inhibitors in sarcoma treatment. What is more, we describe and discuss the possibility and biological rationale for combination therapies with conventional treatments, target therapy and immunotherapy, highlighting potential avenues for future research to integrate CDK inhibition in sarcoma treatment.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1095219